ICH guideline on periodic benefit risk evaluation reporting likely in 2012
This article was originally published in SRA
The International Conference on Harmonisation is working on a new efficacy-related guideline on periodic benefit risk evaluation reporting. The ICH aims to have the document ready for adoption by late 20121.
You may also be interested in...
Sponsors of new and existing medicines in New Zealand will have to update their product labels within specified deadlines to include warning statements about certain allergens.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Companies are being encouraged to become “early adopters” of the EU Clinical Trials Information System when it goes live in December 2021.